1. Home
  2. ADXN vs MBAI Comparison

ADXN vs MBAI Comparison

Compare ADXN & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addex Therapeutics Ltd

ADXN

Addex Therapeutics Ltd

HOLD

Current Price

$5.89

Market Cap

8.6M

Sector

Health Care

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

HOLD

Current Price

$1.04

Market Cap

8.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADXN
MBAI
Founded
2002
2004
Country
Switzerland
Israel
Employees
N/A
85
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6M
8.8M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ADXN
MBAI
Price
$5.89
$1.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.4K
45.9K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$86.57
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.41
$0.95
52 Week High
$12.05
$3.92

Technical Indicators

Market Signals
Indicator
ADXN
MBAI
Relative Strength Index (RSI) 47.00 41.00
Support Level $5.53 $0.95
Resistance Level $7.37 $1.26
Average True Range (ATR) 0.20 0.09
MACD 0.01 0.01
Stochastic Oscillator 33.53 25.84

Price Performance

Historical Comparison
ADXN
MBAI

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: